• Kling’s technology will be used to find difficult-to-detect, immuno-functional antibodies from immortalized human B cells.
• The collaboration aims to speed up the discovery of innovative antibodies to revolutionize disease prevention and treatment.

AMSTERDAM, July 24, 2025 — Kling Bio (“Kling” or “the Company”), a biotechnology company focused on developing antibody-based drugs for cancer and infectious diseases, has announced a collaboration and license option agreement with Sanofi. The agreement focuses on discovering antibodies and epitopes using Kling’s advanced B cell immortalization and screening platform, Kling-Select.

Kling-Select is a proprietary B cell immortalization platform, validated clinically and commercially, that has been crucial in identifying potent neutralizing antibodies. By utilizing patient-derived B cells, Kling-Select allows for the quick identification of new antibodies and conserved viral epitopes, greatly improving vaccine and therapeutic design. Through a function-first screening process, Kling-Select identifies rare and highly effective immune targets, which accelerates the creation of next-generation preventive and therapeutic treatments. The platform has a proven track record, including validated antibody candidates for RSV, COVID-19, and influenza, demonstrating its wide-ranging utility and scientific significance.

The collaboration aims to find and characterize monoclonal antibodies that effectively neutralize a clinically relevant human viral pathogen. The knowledge gained from this collaborative effort could lead to the development of innovative antiviral therapies and inform the creation of more effective vaccine candidates.

“This collaboration with Sanofi demonstrates the extensive potential of our Kling-Select platform to tackle global health issues by enabling the discovery of first-in-class, human-derived antibodies,” said Michael Koslowski, MD, Chief Executive Officer of Kling Bio. “Kling-Select offers valuable insights into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”

About Kling Bio

Kling Bio is a privately held biotechnology company dedicated to discovering and developing new targets and therapeutics. The company is based in Amsterdam, the Netherlands, and holds a complete IP portfolio covering its proprietary platform technologies, Kling-Select and Kling-Evolve. These platforms facilitate the simultaneous discovery of novel, fully human antibodies directly from patient-derived B cells and the targets they recognize.

Kling-Select uses a fully owned and clinically validated B cell immortalization and screening technology to identify new therapeutic antibody binders and targets from patients showing exceptional clinical responses. This technology has successfully found novel neutralizing antibodies for various infectious diseases, including Covid and influenza. More recently, Kling-Select has been used on peripheral and tumor-infiltrating B cells from cancer patients, resulting in a portfolio of new and selective antibody-target pairs. The unbiased nature of this discovery platform allows for the identification of novel targets and unique epitopes that are not accessible through more traditional target discovery methods.

Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of antibody assets in oncology.

SOURCE Kling Bio

“`